ArticleJournal of asthma and allergy2026
Green Light for Response: Clinical Stratification of Response to Biologic Therapy in Severe Asthma.
Article in Journal of asthma and allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Biologic therapies have transformed the management of severe asthma; however, treatment response remains heterogeneous and difficult to anticipate in routine practice. Conventional biomarkers alone have limited ability to identify patients who will achieve complete or sustained clinical benefit. This study aimed to explore baseline clinical and inflammatory thresholds associated with response to biologic therapy and to propose an exploratory, clinically oriented stratification framework. Methods: We conducted a secondary analysis of a real-world, single-center, ambispective cohort of adults with severe uncontrolled asthma treated with biologic therapies and followed for at least 12 months. Clinical response was assessed at 6 and 12 months using the multidimensional EXACTO and FEOS scales. Baseline clinical and biological variables were analyzed using exploratory ROC curve analyses to identify thresholds associated with complete clinical response. Results: Among 64 patients, the proportion of complete responders increased from 14% at 6 months to 32.1% at 12 months. No significant differences in response were observed between biologic agents. Higher baseline blood eosinophil counts and a history of frequent exacerbations were associated with improved outcomes. Exploratory eosinophil thresholds of approximately 440 and 435 cells/µL were identified at 6 and 12 months, respectively. Female sex and nasal polyposis were also associated with higher response rates. Based on these findings, three exploratory response profiles reflecting different likelihoods of response were identified. Conclusion: Baseline clinical and inflammatory characteristics may support response stratification in severe asthma. Given that maximal benefit may be achieved over longer treatment periods, extended follow-up should be considered before modifying biologic therapy. The proposed framework is exploratory and provides a basis for future prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.